Cow's milk protein allergy and intolerance in infancy Some clinical, epidemiological and immunological aspects

Authors


*Department of Pediatrics, Odense University Hospital, DK-5000 Odense C, Denmark

Abstract

Reproducible clinically abnormal reactions to cow's milk protein (CMP) may be due to the interaction between one or more milk proteins and one or more immune mechanisms, possibly any of the four basic types of hypersensitivity reactions. At present, evidence for type I, III and IV reactions against CMP has been demonstrated. Immunologically mediated reactions, mainly immediate IgE-mediated reactions are defined as cow's milk protein allergy (CMPA). Non immunologically reactions against CMP are defined as cow's milk protein intolerance (CMPI). Many studies on “cow's milk allergy” have not investigated the immunological basis of the clinical reactions. It is not possible to differentiate between CMPA and CMPI solely on clinical symptoms. No single laboratory test is diagnostic of CMPA/CMPI. Therefore, the diagnosis still has to be based on strict well-defined elimination and milk challenge procedures. Before 1950 CMPA/CMPI was rarely diagnosed. Since 1970 widely varying estimates of the incidence from 1.8% to 7.5% have been reported, mainly reflecting differences in diagnostic criteria and study design. Based on strict diagnostic criteria the incidence of confirmed CMPA/CMPI in infancy seems to be about 2–5% in developed countries. Symptoms suggestive of CMPA/CMPI may be encountered in about 5–15% of infants emphasizing the importance of controlled elimination/milk challenge. In breastfed infants reproducible clinical reactions to CMP in human milk have been reported in about 0.5%. Most infants with CMPA/CMPI develop symptoms before one month of age, often within one week after introduction of cow's milk based formula. The majority have ≥ 2 symptoms and symptoms from ≥ 2 organ systems. About 50%–70% have cutaneous symptoms, 50–60% gastrointestinal symptoms, and about 20–30% respiratory symptoms. In exclusively breast-fed infants with CMPA/CMPI severe atopic eczema is a predominant symptom. Debut of CMPA/CMPI after 12 months is extremely rare. The basic treatment is complete avoidance of CMP. In infancy a proven hypoallergenic CM substitute is needed. Due to clinically important residual allergenicity in some hypoallergenic formulae controlled clinical testing is necessary in each case before use. Goat's milk proteins share identity with CMP. Raw untreated cow's milk and unhomogenized cow's milk is as allergenic as normal pasteurized and homogenized milk products. The prognosis of CMPA/CMPI is good with a remission rate about 45–50% at one year, 60–75% at two years, and 85–90% at three years. Associated adverse reactions to other foods develop in about 50%, and allergy against inhalants in 50–80% before puberty. High levels of IgE to CMP are associated with an increased risk of persisting CMPA, persisting allergy to other foods and inhalant allergy. The degree of antibody response to CMP exposure is a better predictor of persisting CMPA than a single finding of an elevated antibody level which can occur in normal infants without CMPA/CMPI. Cow's milk proteins are absorbed from the gut and can be measured in the blood in quantities of micrograms per liter serum both in children and adults. Macromolecular absorption is increased in preterm infants and in newborns, and has also been demonstrated in infants with CMPA. Whether an increased macromolecular absorption is a part of an allergic constitution/heredity or is due to temporal mucosal damage is not clarified, and the relevance of an increased absorption for development of clinical disease is unclear. The cow's milk protein, betalactoglobulin can be detected in the breast milk of 95% of lactating women (0.9–150 μg/1, median value 4.2 μg/1) when consecutive continual testing of breast milk is done. Considering the low frequency of CMPA/CMPI these small amounts of CMP in breast milk may rather induce tolerance to CMP than allergic sensitization. The development of CMPA/CMPI primarily seems to depend on the exquisite immune responsiveness in predisposed individuals. A significant association between early neonatal exposure to cow's milk formula feeding and subsequent development of CMPA/CMPI has been documented. Preliminary findings of specific IgE to individual cow's milk proteins in cord blood of the majority of infants with later development of CMP/CMPI may indicate intrauterine sensitization playing a role in the pathogenesis of CMP/CMPI, perhaps as a weak intrauterine priming inducing a low IgE response, which needs to be boostered postnatally in order to cause clinical disease, especially in infants with a marked atopic predisposition.

Ancillary